Highlights Ocugen, Inc.

Equities

OCGN

US67577C1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 20/05/2026 am IST			5-day change	1st Jan Change
1.300 ^USD	-2.99%		-11.56%	-3.70%

15/05	Ocugen Closes Offering of Senior Notes Due 2034	MT
06/05	Ocugen, Inc., Q1 2026 Earnings Call, May 05, 2026

Highlights

05/05	Ocugen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
10/04	Ocugen, Inc. Announces Modifier Gene Therapy Delivers 46% Lesion Reduction in Age-Related Macular Degeneration	CI
01/04	Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of Ocu410st for Stargardt Disease	CI
24/03	Ocugen Inc Announces Topline 12-Month Data from Phase 2 Armada Clinical Trial Evaluating Ocu410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration	CI
04/03	Ocugen, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02/03	Ocugen Announces Phase 3 Limelight Enrollment Completion for Ocu400, A Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa	CI
23/01	Ocugen Closes $20.9 Million Registered Direct Offering	MT
15/01	Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration	CI
05/11	Ocugen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
05/11	Tranche Update on Ocugen, Inc.'s Equity Buyback Plan announced on October 9, 2019.	CI
05/11	Biotech firm Ocugen's Q3 revenue beats expectations	RE
18/25/18	Ocugen Inc says on Sept 16, carisma terminates merger agreement with Ocugen	RE
15/25/15	Ocugen Licenses Korean Rights to Gene Therapy OCU400 in $7.5 Million Deal With Kwangdong	MT
15/25/15	Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea	CI
13/25/13	Ocugen Receives European Medicines Agency Committee's Acceptance for OCU410ST Study	MT
13/25/13	Ocugen gets EMA backing on OCU410ST approval pathway for Stargardt gene therapy	RE
13/25/13	Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST--Modifier Gene Therapy for Stargardt Disease	CI
04/25/04	Tranche Update on Ocugen, Inc.'s Equity Buyback Plan announced on October 9, 2019.	CI
02/25/02	Ocugen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
01/25/01	Biotech firm Ocugen's Q2 revenue beats expectations at $1.37 mln	RE
18/25/18	Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST	CI
16/25/16	Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of Ocu410st	CI
05/25/05	Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of Ocu400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea	CI
05/25/05	Ocugen Signs Deal for Korean Rights to Gene Therapy OCU400	MT
27/25/27	Ocugen Announces Rare Pediatric Disease Designation Granted For Ocu410st--Modifier Gene Therapy For The Treatment Of Stargardt Disease	RE